Lower baseline quantitative HBcAb may help predict response to sequential combination therapy with IFN, rhIL-2 and HBV therapeutic vaccine in entecavir-suppressed CHB patients
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Inst & Dept Infect Dis, Wuhan, Hubei, Peoples R China;
推荐引用方式(GB/T 7714)：
Yan W.,Yuan Q.,Wu D.,et al.Lower baseline quantitative HBcAb may help predict response to sequential combination therapy with IFN, rhIL-2 and HBV therapeutic vaccine in entecavir-suppressed CHB patients[J].JOURNAL OF HEPATOLOGY.2018,68:S475-S475.doi:10.1016/S0168-8278(18)31198-X.
APA：
Yan, W.,Yuan, Q.,Wu, D.,Han, M.,Chen, G....&Ning, Q..(2018).Lower baseline quantitative HBcAb may help predict response to sequential combination therapy with IFN, rhIL-2 and HBV therapeutic vaccine in entecavir-suppressed CHB patients.JOURNAL OF HEPATOLOGY,68,
MLA：
Yan, W.,et al."Lower baseline quantitative HBcAb may help predict response to sequential combination therapy with IFN, rhIL-2 and HBV therapeutic vaccine in entecavir-suppressed CHB patients".JOURNAL OF HEPATOLOGY 68.(2018):S475-S475
医学